Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Second chance: new study explores rescue ovulation for failed IVF egg retrieval

NCT ID NCT06502665

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at 87 women who had no eggs retrieved during their first IVF cycle. Researchers wanted to see if a second round of ovulation-inducing medication could lead to successful egg retrieval. The goal was to understand which factors might predict failure and how to improve outcomes for future IVF attempts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hormonal medications (hCG or GnRHa) for ovulation induction
What this could lead to
If successful, this could help doctors identify women at risk of failed egg retrieval and adjust their treatment to improve IVF outcomes.
What could go wrong
This is a small, completed observational study, not a controlled trial. The findings may not apply to all IVF patients and do not guarantee better pregnancy rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

87 people

The number who actually took part.

Started

Jul 2024

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Electronic medical record from 2018 to 2023 of patients having undergone an IVF cycle

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with no oocytes retrieved in the first ovum pick-up Exclusion Criteria: * Error in trigger medication or timing by the patient/ medical team * Major absence of information (primary objective, trigger medication, time interval of trigger and ovum pick-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertility are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinique Ovo

    Montreal, Quebec, H4P 2S4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.